Compare Monster Beverage Corp (MNST) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs GeneDx Holdings Corp — how do they compare? Monster Beverage Corp trades at $42.85 (market cap $83.93B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Monster Beverage Corp is far larger — about 32.5× GeneDx Holdings Corp's market cap, and Monster Beverage Corp is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| MNST | WGS | |
|---|---|---|
Market Cap | $83.93B | $2.58B |
Sector | Consumer Staples | Technology |
52-Week High | $49.97 | $167.51 |
52-Week Low | $31.41 | $34.51 |
Enterprise Value | $82.22B | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed in August 2026. The stock exhibits a bullish technical signal from oscillators despite bearish moving averages, with key support at $42. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with $0.30 EPS, and shows robust revenue growth, with 2025 revenue reaching $8.29 billion and net income of $1.91 billion. Profitability remains high, with a net margin of 23.08% and ROE of 25.7%.
The outlook for MNST is positive, driven by consistent earnings beats, international expansion accounting for 46% of sales, and analyst consensus favoring a buy rating with a $51.10 price target. Key risks include elevated valuation multiples, such as a P/E of 39.95, and competitive pressures in the energy drink sector. Investors should weigh growth prospects against premium pricing.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
